Goldman has a buy rating and $325.40 price target on CSL's shares. This implies potential upside of 19% for investors over ...

The note reveals that Goldman has initiated coverage with a buy rating and $48.90 price target on ResMed's shares. Based on ...

Trump’s executive orders included overhauls to U.S. trade policy and declaring a national emergency at the southern border.

ResMed Inc. (ASX: RMD ... We believe GLP-1 drugs to treat OSA will co-exist with CPAP therapy based on the published clinical data and payor policies to date. Engagement on RMD's patient app ...

ResMed makes CPAP machines and equipment to treat OSA. Harrison expects both weight loss drugs and wearables are raising awareness of the condition, which causes breathing to be interrupted while ...

The global anti-snoring devices market, valued at US$ 0.83 billion in 2023, is forecasted to grow at a robust CAGR of 9.8%, reaching US$ 0.91 ...

Here's why brokers are feeling bullish about these three shares this week. The post Brokers name 3 ASX shares to buy today ...

How often should you replace your CPAP supplies may be determined in part by your insurance ... has two integrated filters that can be replaced with this same frequency. The ResMed AirSense machines ...

Goldman Sachs initiated coverage of ResMed (RMD) with a Buy rating and A$48.90 price target The firm says its Buy thesis is based on “robust” ...